Bristol-Myers Squibb Co
LSE:0R1F
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bristol-Myers Squibb Co
LSE:0R1F
|
US |
|
Danone SA
OTC:GPDNF
|
FR |
|
O
|
Orix Corp
XBER:OIX
|
JP |
|
Bioretec Oy
F:0TN
|
FI |
|
A
|
Amrize AG
NYSE:AMRZ
|
US |
|
L
|
LGL Group Inc
AMEX:LGL
|
US |
|
Matas A/S
LSE:0QFA
|
DK |
|
O
|
Origin Bancorp Inc
F:36Z
|
US |
|
S
|
Stora Enso Oyj
XBER:ENUR
|
FI |
|
N
|
NXP Semiconductors NV
F:VNX
|
NL |
|
U
|
Ulta Beauty Inc
SWB:34U
|
US |
Wall St Price Targets
0R1F Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for 0R1F is 62.27 USD with a low forecast of 32.96 USD and a high forecast of 77.63 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0R1F's stock price target?
Price Target
62.27
USD
According to Wall Street analysts, the average 1-year price target for 0R1F is 62.27 USD with a low forecast of 32.96 USD and a high forecast of 77.63 USD.
What is the Revenue forecast for Bristol-Myers Squibb Co?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is -3%.
What is the Operating Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 8 years is -3%.
What is the Net Income forecast for Bristol-Myers Squibb Co?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 8 years is 6%.
